These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37457251)

  • 1. A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult.
    Ngamprasertchai T; Kositamongkol C; Lawpoolsri S; Rattanaumpawan P; Luvira V; Chongtrakool P; Kaewkungwal J; Chokephaibulkit K; Phisalprapa P
    Front Public Health; 2023; 11():1071117. PubMed ID: 37457251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.
    Choi MJ; Kang SO; Oh JJ; Park SB; Kim MJ; Cheong HJ
    Hum Vaccin Immunother; 2018; 14(8):1914-1922. PubMed ID: 29953307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
    Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
    JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine.
    Gouveia M; Jesus G; Inês M; Costa J; Borges M
    Hum Vaccin Immunother; 2019; 15(4):850-858. PubMed ID: 30633615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
    Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
    Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
    Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
    Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?
    Kulpeng W; Leelahavarong P; Rattanavipapong W; Sornsrivichai V; Baggett HC; Meeyai A; Punpanich W; Teerawattananon Y
    Vaccine; 2013 Jun; 31(26):2839-47. PubMed ID: 23588084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
    Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program.
    Stoecker C; Kobayashi M; Matanock A; Cho BH; Pilishvili T
    Vaccine; 2020 Feb; 38(7):1770-1777. PubMed ID: 31889609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
    Guo J; Zhang H; Zhang H; Lai X; Wang J; Feng H; Fang H
    Vaccine; 2023 Jan; 41(3):716-723. PubMed ID: 36522264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.
    Feldman C; Dlamini SK; Madhi SA; Meiring S; von Gottberg A; de Beer JC; de Necker M; Stander MP
    PLoS One; 2020; 15(1):e0227945. PubMed ID: 31995597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States.
    Stoecker C; Kim L; Gierke R; Pilishvili T
    J Gen Intern Med; 2016 Aug; 31(8):901-8. PubMed ID: 26976292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of pneumococcal vaccines for adults in the United States.
    Chen J; O'Brien MA; Yang HK; Grabenstein JD; Dasbach EJ
    Adv Ther; 2014 Apr; 31(4):392-409. PubMed ID: 24718851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
    Kang DW; Kim CR; Song JY; Park SK
    Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis.
    Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    Hum Vaccin Immunother; 2019; 15(4):863-872. PubMed ID: 30633706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults.
    Smith KJ; Nowalk MP; Raymund M; Zimmerman RK
    Vaccine; 2013 Aug; 31(37):3950-6. PubMed ID: 23806240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.